Dlouhé nekódující RNA a karcinom z renálních buněk

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Long non-coding RNAs and renal cell carcinoma
Authors

FEDORKO Michal BOHOŠOVÁ Júlia POPRACH Alexandr PACÍK Dalibor

Year of publication 2020
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.linkos.cz/casopis-klinicka-onkologie/2020-10-21-5/dlouhe-nekodujici-rna-a-karcinom-z-renalnich-bunek/
Doi http://dx.doi.org/10.14735/amko2020340
Keywords biomarker; diagnosis; long non-coding RNA; renal cell carcinoma; prognosis
Description Background: To provide an overview of the importance of long non-coding RNAs (lncRNAs) in the pathogenesis of renal cell carcinoma and their utility as bio­markers for dia­gnosis, prognosis and prediction of treatment response. Materials and methods: A literature search in the Pubmed and Web of Science databases using the keywords variations of “long non-coding RNA” (“lncRNA”, “long noncoding RNA”, “long non-coding RNA”) and “renal cell carcinoma” (“renal cancer”, “renal cell carcinoma”, “kidney cancer”) was performed. The results related to the pathogenesis, dia­gnosis, prognosis and use as therapeutic targets were separated. Results: Long non-coding RNAs regulate gene expression at different levels. They act both as oncogenes and tumor suppressors. The mechanism of their action has not been fully elucidated, but they are actively involved in the regulation of hypoxia inducible factors pathway, epithelial-mesenchymal transition, cell proliferation, cell cycle regulation, apoptosis, local invasion and development of metastases. Aberrant expression in tumor tissue compared to healthy parenchyma and the correlation of expression levels with clinical-pathological features allow the potential use of many lncRNAs as bio­markers for early detection and prognosis of the disease, including the response to targeted therapy. In vitro assays indicate the potential use of lncRNAs as therapeutic targets. Conclusion: Our knowledge of long non-coding RNAs in relation to renal cell carcinoma is increasing rapidly. At present, some of them can be considered as promising bio­markers. Further research is needed before they can be introduced into routine clinical practice.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.